Details of the Drug

General Information of Drug (ID: DM2LXB1)

Drug Name

BNT113

Indication

Disease Entry	ICD 11	Status	REF
Head and neck cancer	2D42	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Vaccine

Cross-matching ID

References

1	ClinicalTrials.gov (NCT04534205) An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT). U.S.National Institutes of Health.